[Form 4] Editas Medicine, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Linda C. Burkly, Executive Vice President and Chief Scientific Officer of Editas Medicine, reported a sale of 710 shares of the issuer's common stock on 09/03/2025 at a price of $2.5961 per share. The filing states the sale was effected under a durable automatic sales instruction plan adopted July 3, 2023, to satisfy tax withholding triggered by restricted stock units that vested on 09/02/2025, and the sale was not a discretionary trade. Following the transaction Burkly beneficially owns 69,490 shares, which includes 5,802 shares acquired under the company Employee Stock Purchase Plan.

Insights

Securities Analyst

TL;DR: Routine insider sale under a pre-existing plan to cover tax withholding; no discretionary trading reported, neutral for valuation.

The Form 4 discloses a small, non-discretionary sale of 710 shares at $2.5961 executed under an automatic instruction plan tied to RSU vesting. Because the filing explicitly states the transaction was to satisfy tax withholding obligations and was not discretionary, it lacks the market-timing implications of opportunistic insider sales. The residual beneficial ownership of 69,490 shares signals continued equity alignment by the reporting officer. Impact on capitalization or control is immaterial given the small size of the sale relative to her holdings and typical outstanding share counts for public companies.

Corporate Governance Expert

TL;DR: Disclosure aligns with good governance: use of a Rule 10b5-1-type plan and clear explanation reduces regulatory and signaling concerns.

The filing identifies a durable automatic sales instruction plan adopted in 2023 and explicitly ties the sale to tax withholding from RSU vesting on 09/02/2025. Clear description of the plan and the non-discretionary nature of the sale supports transparency and compliance with Section 16 reporting requirements. There are no indications of amendments, joint filings, or other governance issues in the disclosed content.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Burkly Linda

(Last) (First) (Middle)

11 HURLEY ST.

(Street)

CAMBRIDGE MA 02141

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Editas Medicine, Inc. [ EDIT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP, CHIEF SCIENTIFIC OFFICER

3. Date of Earliest Transaction (Month/Day/Year)
09/03/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/03/2025		S(1)		710	D	$2.5961	69,490(2)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Sale was effected pursuant to a durable automatic sales instruction plan adopted by the Reporting Person on July 3, 2023, and represents the sale of shares by the Issuer necessary to meet tax withholding obligations as a result of vesting in restricted stock units on September 2, 2025. The sale does not represent a discretionary trade by the Reporting Person.

2. The amount of securities beneficially owned following the reported transaction includes 5,802 shares acquired under the Issuer's Employee Stock Purchase Plan.

Remarks:

	/s/ Linda C. Burkly	09/04/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What transaction did Editas Medicine insider Linda C. Burkly report on Form 4?

The Form 4 reports a sale of 710 shares on 09/03/2025 at $2.5961 per share.

Why were the shares sold by Linda C. Burkly?

The filing states the sale was made to meet tax withholding obligations from restricted stock units that vested on 09/02/2025.

Was the sale a discretionary trade by the reporting person?

No. The Form 4 specifies the sale was effected pursuant to a durable automatic sales instruction plan and was not discretionary.

How many Editas shares does Linda C. Burkly beneficially own after the reported transaction?

She beneficially owns 69,490 shares following the transaction, which includes 5,802 ESPP shares.

What is Linda C. Burkly's role at Editas Medicine as listed on the filing?

She is listed as EVP, Chief Scientific Officer and an officer reporting under Section 16.